Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial-MedSci.cn

Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial

Bennett, SR; McCarty, JM; Ramanathan, R; Mendy, J; Richardson, JS; Smith, J; Alexander, J; Ledgerwood, JE; de Lame, PA; Tredo, SR; Warfield, KL; Bedell, L

Bedell, L (通讯作者)，Emergent BioSolut, Gaithersburg, MD 20879 USA.

LANCET INFECTIOUS DISEASES, 2022; 22 (9): 1343

科室
- - 订阅+
  - 更多科室
工具
服务